Status:
COMPLETED
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Donaghue Medical Research Foundation
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections an...
Detailed Description
Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder
- Exclusion
- Pregnant or lactating
Exclusion
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00237809
Start Date
September 1 2002
End Date
September 1 2012
Last Update
May 10 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06508
2
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516